Literature DB >> 21231777

Lipoprotein(a) and risk of myocardial infarction--genetic epidemiologic evidence of causality.

Pia R Kamstrup1, Anne Tybjærg-Hansen, Børge G Nordestgaard.   

Abstract

Elevated levels of lipoprotein(a) are associated with an increased risk of myocardial infarction. Our study aimed to test whether genetic data are consistent with this association being causal. Accordingly, we developed a high-throughput realtime PCR assay to genotype for the lipoprotein(a) kringle IV type 2 (KIV-2) repeat polymorphism in the LPA gene in > 40,000 individuals. The LPA KIV-2 genotype associated with plasma levels of lipoprotein(a) (trend p < 0.001), and the LPA KIV-2 genotype associated with risk of myocardial infarction (trend p < 0.001 to 0.03) in a manner consistent with its effect on plasma levels of lipoprotein(a). The association of LPA KIV-2 genotypes raising plasma levels of lipoprotein(a) with increased risk of myocardial infarction strongly supports a causal association of lipoprotein(a) with risk of myocardial infarction.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21231777     DOI： 10.3109/00365513.2010.550311

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN： 0036-5513            Impact factor:   1.713


  13 in total

1.  Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses.

Authors:  Nguyen T Nguyen; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

2.  Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.

Authors:  Jenny Sandmark; Anna Tigerström; Tomas Akerud; Magnus Althage; Thomas Antonsson; Stefan Blaho; Cristian Bodin; Jonas Boström; Yantao Chen; Anders Dahlén; Per-Olof Eriksson; Emma Evertsson; Tomas Fex; Ola Fjellström; David Gustafsson; Margareta Herslöf; Ryan Hicks; Emelie Jarkvist; Carina Johansson; Inge Kalies; Birgitta Karlsson Svalstedt; Fredrik Kartberg; Anne Legnehed; Sofia Martinsson; Andreas Moberg; Marianne Ridderström; Birgitta Rosengren; Alan Sabirsh; Anders Thelin; Johanna Vinblad; Annika U Wellner; Bingze Xu; Ann-Margret Östlund-Lindqvist; Wolfgang Knecht
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

3.  Flaxseed Oil Supplementation Improve Gene Expression Levels of PPAR-γ, LP(a), IL-1 and TNF-α in Type 2 Diabetic Patients with Coronary Heart Disease.

Authors:  Ali Akbar Hashemzadeh; Nikoo Nasoohi; Fariba Raygan; Esmat Aghadavod; Elmira Akbari; Mohsen Taghizadeh; Mohammad Reza Memarzadeh; Zatollah Asemi
Journal:  Lipids       Date:  2017-09-15       Impact factor: 1.880

4.  Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Authors:  John Ford; Matt Lawson; David Fowler; Nobuko Maruyama; Seiji Mito; Koichi Tomiyasu; Shuji Kinoshita; Chisa Suzuki; Atsuhiro Kawaguchi; Patrick Round; Malcolm Boyce; Steve Warrington; Werner Weber; Sander van Deventer; John J P Kastelein
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 5.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

6.  Changes of Certain Metabolic and Cardiovascular Markers Fructosamine, H-FABP and Lipoprotein (a) in Patients with Hypothyroidism.

Authors:  Ahmed Naseer Kaftan; Farah H Naser; Muslim A Enaya
Journal:  Med Arch       Date:  2021-02

Review 7.  South Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology.

Authors:  Latha Palaniappan; Arun Garg; Enas Enas; Henrietta Lewis; Sehrish Bari; Martha Gulati; Cristina Flores; Ashish Mathur; Cesar Molina; Jagat Narula; Shahid Rahman; Jennifer Leng; Francesca Gany
Journal:  J Community Health       Date:  2018-12

8.  Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Authors:  Vybhav Jetty; Charles J Glueck; Kevin Lee; Naila Goldenberg; Marloe Prince; Ashwin Kumar; Michael Goldenberg; Ishan Anand; Ping Wang
Journal:  Vasc Health Risk Manag       Date:  2017-07-06

9.  The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Authors:  Manjinder S Sandhu; Nita G Forouhi; Zheng Ye; Philip C Haycock; Deepti Gurdasani; Cristina Pomilla; S Matthijs Boekholdt; Sotirios Tsimikas; Kay-Tee Khaw; Nicholas J Wareham
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

10.  Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.

Authors:  Marianne Månsson; Inge Kalies; Göran Bergström; Caroline Schmidt; Anne Legnehed; Lillemor Mattsson Hultén; Lena Amrot-Fors; David Gustafsson; Wolfgang Knecht
Journal:  Sci Rep       Date:  2014-06-17       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.